Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
KEYMED BIO-B Receives USD45M Milestone Payment for CMG901 License Agreement
Recommend 1 Positive 0 Negative 2 |
||||
|
||||
|
KEYMED BIO-B (02162.HK) announced that AstraZeneca had initiated a multi-center, randomized, controlled Phase III clinical study of sonesitatug vedotin (AZD0901, or CMG901) in combination with capecitabine, with or without rilvegostomig for the first-line treatment of Claudin 18.2-positive and HER2-negative advanced/metastatic gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma (CLARITY-Gastric 02), and the first subject has received the first dose. Subject to the terms and conditions of the license agreement between KEYMED BIO-B and AstraZeneca, the dosage of the first subject in the above clinical trial has triggered a milestone payment of USD45 million in total. KEYMED BIO-B has received the payment from AstraZeneca. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
